The agreement encompasses development and commercial milestones for the products, which could amount to up to $180m.

The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple ...

Alvotech (ALVO) stock is in focus as the company partners with Advanz Pharma to market three additional biosimilars across ...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to ...

Learn more about whether Alvotech or Arrowhead Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

Teva and Alvotech announced that the U.S. Food and Drug Administration (FDA) approved SELARSDI (ustekinumab-aekn) injection as ...

REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 8, 2025) - Alvotech (NASDAQ: ALVO, the "Company"), a global biotech company specializing in the development and manufacture of biosimilar medicines ...

REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 16, 2025) — Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 16, 2025) - Alvotech (NASDAQ: ALVO, the "Company"), a global biotech company specializing in the development and manufacture of biosimilar medicines ...